STAT+: The biotech startups skipping AI for drug discovery
Reported by STAT News · all stories from statnews.com
Editorial digest
A report highlights emerging biotechnology companies that are deliberately opting out of machine learning in their pharmaceutical research pipelines. The coverage examines alternative pathways ventures are pursuing rather than relying on computational discovery models.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/14/2026
STAT+: The startup chasing ‘general biological intelligence’
A new company is pursuing advanced biological AI capabilities.
- Trusted health newsroom9/2/2026
STAT+: How a former ARPA-H director’s startup is tackling AI’s ‘dumb problems’
A startup led by a former ARPA-H director is addressing common AI challenges.
- Trusted health newsroom8/5/2026
STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI
Schrödinger CEO Ramy Farid reassessed his views on AI.
- Trusted health newsroom10/23/2026
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
Pathos has secured $237 million in financing, elevating the artificial intelligence drugmaker's estimated value to $3 billion.
- Trusted health newsroom10/21/2026
STAT+: What’s the deal with Isomorphic Labs?
A new report examines the current standing and operations of drug discovery venture Isomorphic Labs.
- Trusted health newsroom10/28/2026
STAT+: Why every health care AI company must face Epic
A report examines why developers of medical artificial intelligence must inevitably contend with electronic health record giant Epic.